Announcements Trials
Browse Landscape

Phase

Phase NA 3Phase 2 2Phase EARLY_PHASE1 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Neurofibromatosis 1 2Attention Deficit Disorder with Hyperactivity 1

Interventions

Cisplatin 1041Cyclophosphamide 973Carboplatin 954Radiotherapy 893Bevacizumab 847Gemcitabine 817pembrolizumab 759Paclitaxel 738Docetaxel 734Oxaliplatin 706Capecitabine 649Fluorouracil 564Rituximab 559Nivolumab 506Dexamethasone 487Etoposide 468Doxorubicin 458Irinotecan 442Drug Therapy 402Leucovorin 377Cytarabine 342Cetuximab 340Lenalidomide 326Trastuzumab 323Pemetrexed 315durvalumab 295Filgrastim 287Magnetic Resonance Spectroscopy 278Temozolomide 275Prednisone 274

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × OTHER × Inhalation × Clear all
NCT04481048 2026-06-05

DoDNAC

Children's Hospital Medical Center, Cincinnati

Phase 2 Completed
25 enrolled 12 charts
CNS

Attention Deficit Disorder with Hyperactivity, Neurofibromatosis 1

NCT04481035 2026-04-21

NF1NAC

Children's Hospital Medical Center, Cincinnati

Phase 2 Completed
5 enrolled 10 charts
CNS

Neurofibromatosis 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡